Diabetes awareness survey reveals alarming figures across the Middle East and Northern Africa regions

Novo NordiskIn the lead up to World Diabetes Day 2010 on 14 November Novo Nordisk and Ipsos Emirates Health conducted a survey in ten countries of the Middle East and Northern Africa (MENA) region: Algeria, Egypt, Iran, Iraq, Jordan, Lebanon, Morocco, Kingdom of Saudi Arabia (KSA), Tunisia and the United Arab Emirates (UAE).

The survey, which was carried out in October this year, assesses the level of awareness among the general population when it comes to causes, risks and complications of diabetes. It also looks into respondents' risk of developing diabetes. With over 3,000 interviews, the respondents were representative of the demographic and socio-economic profile in each country.

The survey shows that 41% of respondents are at risk of developing diabetes. Despite a high awareness level of the scale of the disease, only one in two respondents consider diabetes to be a severe or a very severe disease. Myths about diabetes also remain very common:

  • 31% of Algerian respondents believe that diabetes is contagious
  • Stress was ranked as a leading cause of diabetes across the region (39%)
  • Half of respondents (52%) declared that stroke cannot be caused by diabetes

"The results of the MENA diabetes awareness survey are striking. The need to further educate the general public about the risk factors, complications and the severity of the condition is very clear. We hope that the initiative will inspire authorities to tackle this issue. We believe that early detection of diabetes, prevention and education can make a real difference," said Lise Kingo, executive vice president and chief of staffs at Novo Nordisk.

Diabetes is sweeping the MENA region affecting an estimated 26.6 million people today, creating overwhelming demands on the region's healthcare systems and huge financial burdens on its governments. As alarming as this picture is, the number of people with diabetes is expected to double to 51.7 million people by 2030.

About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit novonordisk.com.

Most Popular Now

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...

Biomarkers found that could be drug targets agains…

Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Cent...